Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis.

@article{Hyun2012ComparisonOT,
  title={Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis.},
  author={Jong Jin Hyun and Yeon Seok Seo and Eileen L Yoon and Tae Hyung Kim and Dong Jin Kim and Hyun Seok Kang and Eun Suk Jung and Jeong Han Kim and Hyonggin An and Ji Hoon Kim and Hyung Joon Yim and Jong Eun Yeon and Hong Sik Lee and Kwan Soo Byun and Soon Ho Um and Chang Duck Kim and Ho Ryu},
  journal={Liver international : official journal of the International Association for the Study of the Liver},
  year={2012},
  volume={32 4},
  pages={656-64}
}
BACKGROUND Suppression of hepatitis B virus (HBV) DNA is more potent, and occurrence of resistant strain is rare with entecavir than lamivudine, but whether these merits result in a more favourable outcome in HBV-related decompensated cirrhosis patients is unclear. AIMS To compare virologic response, changes in liver function, clinical course and predictive factors for early mortality after treatment between patients treated with lamivudine and those with entecavir in HBV-related… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…